bosutinib
Showing 1 - 25 of 39
Describe Real World Use of Bosutinib inSingle Centre in Scotland
Completed
- Myeloid Leukemia
- Bosutinib
-
Glasgow, United Kingdomeatson West of Scotland Cancer Centre
May 3, 2022
NSCLC, Mesothelioma, Bladder Cancer Trial in Augusta (Bosutinib, Pemetrexed)
Completed
- Carcinoma, Non-Small-Cell Lung
- +7 more
- Bosutinib
- Pemetrexed
-
Augusta, GeorgiaAugusta University Georgia Cancer Center
Jun 10, 2022
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Recruiting
- Metastatic Breast Cancer
- +2 more
- Palbociclib
- +2 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center
Jan 17, 2022
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Completed
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- +6 more
- Bosutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Mar 25, 2022
Leukemia, Chronic Myelogenous Trial in Japan (Bosutinib)
Completed
- Leukemia, Chronic Myelogenous
- Bosutinib
-
Toyoake-City, Aichi, Japan
- +20 more
Apr 26, 2022
Landscape and Real-life Treatment Outcomes in Hungary: Analysis
Completed
- Chronic Myeloid Leukaemia
- Bosutinib
- +4 more
-
Budapest, HungaryPfizer
Dec 15, 2022
Chronic Myeloid Leukemia Trial in Italy (Bosutinib)
Completed
- Chronic Myeloid Leukemia
- Bosutinib
-
Alessandria, Italy
- +44 more
Feb 2, 2023
Safety And Efficacy Of Bosutinib
Recruiting
- Chronic Myelogenous Leukemia
- Bosutinib
-
Shibuya-ku, Japan(unnamed)
Dec 29, 2020
Amyotrophic Lateral Sclerosis Trial in Japan (Bosutinib)
Recruiting
- Amyotrophic Lateral Sclerosis
- Bosutinib
-
Kyoto, Japan
- +3 more
Feb 3, 2021
Chronic Myelogenous Leukemia Trial in Worldwide (Asciminib, Bosutinib)
Active, not recruiting
- Chronic Myelogenous Leukemia
- Asciminib
- Bosutinib
-
Chicago, Illinois
- +87 more
Jan 20, 2023
Accelerated Phase Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Phase
Terminated
- Accelerated Phase Chronic Myelogenous Leukemia (CML)
- +3 more
- Axitinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Nov 17, 2020
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in Moscow
Active, not recruiting
- Chronic Myeloid Leukemia
- +2 more
- Imatinib
- +3 more
-
Moscow, Russian FederationNational Research Center for Hematology
Oct 1, 2020
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +13 more
-
Edmonton, Alberta, Canada
- +9 more
Jan 9, 2023
Previously Treated PH + CML Trial in Worldwide (Bosutinib)
Terminated
- Previously Treated PH + CML
- Bosutinib
-
Los Angeles, California
- +47 more
Dec 2, 2021
Mild Cognitive Impairment, Dementia Trial in Santa Monica (bosutinib)
Enrolling by invitation
- Mild Cognitive Impairment
- Dementia
- bosutinib
-
Santa Monica, CaliforniaNeurological Associates of West LA
Feb 25, 2021
Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30
Terminated
- Blasts Under 15 Percent of Bone Marrow Nucleated Cells
- +4 more
- Bosutinib
- Laboratory Biomarker Analysis
-
Houston, TexasM D Anderson Cancer Center
Apr 22, 2020
Leukemia, Myelogenous, Chronic Trial in Monza, Milano (Bosutinib, Bone Marrow Transplant, Bone Marrow cells)
Completed
- Leukemia
- +3 more
- Bosutinib
- +2 more
-
Monza, Italy/MB, Italy
- +1 more
Nov 3, 2020
Chronic Myeloblastic Leukaemia Trial in Spain (Bosutinib)
Completed
- Chronic Myeloblastic Leukaemia
- Bosutinib
-
Gran Canaria, Spain
- +12 more
Apr 28, 2020
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Trial in Worldwide (Imatinib, Nilotinib, Bosutinib)
Recruiting
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Imatinib
- +4 more
-
Longmont, Colorado
- +128 more
Aug 1, 2022
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Uijeongbu si (Asciminib single agent, Asciminib, Imatinib)
Recruiting
- Chronic Myelogenous Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Asciminib single agent
- +5 more
-
Ann Arbor, Michigan
- +49 more
Jan 26, 2023
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in United States (Bosutinib, Dasatinib, Laboratory Biomarker
Active, not recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Bosutinib
- +5 more
-
Anchorage, Alaska
- +540 more
Dec 14, 2022
Describe The Real World Use Of Bosutinib In The UK And
Completed
- Chronic Myeloid Leukaemia
- Bosutinib
-
Liverpool, Merseyside, United Kingdom
- +2 more
May 1, 2019
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive Trial in Worldwide
Completed
- Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
- Bosutinib
- Imatinib
-
Anaheim, California
- +188 more
Apr 16, 2021